BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 35925070)

  • 1. [Treatment of metastatic pancreatic cancer].
    Heinemann V; Boeck S; Westphalen CB
    Inn Med (Heidelb); 2022 Aug; 63(8):851-862. PubMed ID: 35925070
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Microsatellite instability/mismatch repair deficiency in pancreatic cancers: the same or different?
    Luchini C; Grant RC; Scarpa A; Gallinger S
    Gut; 2021 Oct; 70(10):1809-1811. PubMed ID: 33468535
    [No Abstract]   [Full Text] [Related]  

  • 3. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part I-Colorectal Cancer: Microsatellite Instability, Testing, and Clinical Implications.
    Marginean EC; Melosky B
    Arch Pathol Lab Med; 2018 Jan; 142(1):17-25. PubMed ID: 29144791
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Durable Response to Pembrolizumab in a Patient with Uterine Serous Carcinoma and Lynch Syndrome due to the MSH6 Germline Mutation.
    T Danley K; Schmitz K; Ghai R; Sclamberg JS; Buckingham LE; Burgess K; Kuzel TM; Usha L
    Oncologist; 2021 Oct; 26(10):811-817. PubMed ID: 34018286
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy in pancreatic cancer and the importance of tumour testing.
    Ngo P; Shanshal M; Rojan A
    BMJ Case Rep; 2020 Jul; 13(7):. PubMed ID: 32675128
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment strategies for DNA repair-deficient prostate cancer.
    Teply BA; Antonarakis ES
    Expert Rev Clin Pharmacol; 2017 Aug; 10(8):889-898. PubMed ID: 28573914
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Importance of Distinguishing Sporadic Cancers from Those Related to Cancer Predisposing Germline Mutations.
    Sorscher S
    Oncologist; 2018 Nov; 23(11):1266-1268. PubMed ID: 29866945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined Antiangiogenic Therapy and Immunotherapy Is Effective for Pancreatic Cancer With Mismatch Repair Proficiency but High Tumor Mutation Burden: A Case Report.
    Chen M; Yang S; Fan L; Wu L; Chen R; Chang J; Hu J
    Pancreas; 2019 Oct; 48(9):1232-1236. PubMed ID: 31609933
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rapid Progression of Metastatic Pancreatic Adenocarcinoma During Platinum-Based Therapy in a Patient Harboring a Pathogenic BRCA2 Germline Variant.
    Sorscher S; Ramkissoon S
    Oncologist; 2021 Nov; 26(11):916-918. PubMed ID: 34309133
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pancreatic ductal adenocarcinoma harboring microsatellite instability / DNA mismatch repair deficiency. Towards personalized medicine.
    Lupinacci RM; Bachet JB; André T; Duval A; Svrcek M
    Surg Oncol; 2019 Mar; 28():121-127. PubMed ID: 30851885
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mismatch-repair-deficient metastatic pancreatic ductal adenocarcinoma with a germline PALB2 mutation: unusual genetics, unusual clinical course.
    Boeck S; Mehraein Y; Ormanns S; Kruger S; Westphalen CB; Haas M; Jung A; Kirchner T; Heinemann V
    Ann Oncol; 2017 Feb; 28(2):438-439. PubMed ID: 27803004
    [No Abstract]   [Full Text] [Related]  

  • 12. Clinical and molecular characterisation of hereditary and sporadic metastatic colorectal cancers harbouring microsatellite instability/DNA mismatch repair deficiency.
    Cohen R; Buhard O; Cervera P; Hain E; Dumont S; Bardier A; Bachet JB; Gornet JM; Lopez-Trabada D; Dumont S; Kaci R; Bertheau P; Renaud F; Bibeau F; Parc Y; Vernerey D; Duval A; Svrcek M; André T
    Eur J Cancer; 2017 Nov; 86():266-274. PubMed ID: 29055842
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Maintenance Olaparib for Germline
    Golan T; Hammel P; Reni M; Van Cutsem E; Macarulla T; Hall MJ; Park JO; Hochhauser D; Arnold D; Oh DY; Reinacher-Schick A; Tortora G; Algül H; O'Reilly EM; McGuinness D; Cui KY; Schlienger K; Locker GY; Kindler HL
    N Engl J Med; 2019 Jul; 381(4):317-327. PubMed ID: 31157963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Should platinum-based chemotherapy be preferred for germline BReast CAncer genes (BRCA) 1 and 2-mutated pancreatic ductal adenocarcinoma (PDAC) patients? A systematic review and meta-analysis.
    Rebelatto TF; Falavigna M; Pozzari M; Spada F; Cella CA; Laffi A; Pellicori S; Fazio N
    Cancer Treat Rev; 2019 Nov; 80():101895. PubMed ID: 31542591
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathological response following neoadjuvant immunotherapy in mismatch repair-deficient/microsatellite instability-high locally advanced, non-metastatic colorectal cancer.
    Kothari A; White MG; Peacock O; Kaur H; Palmquist SM; You N; Taggart M; Salem U; Overman M; Kopetz S; Chang GJ
    Br J Surg; 2022 May; 109(6):489-492. PubMed ID: 35576377
    [No Abstract]   [Full Text] [Related]  

  • 16. A new targeted treatment for patients with a germline
    Verdaguer H; Acosta D; Macarulla T
    Future Oncol; 2020 Nov; 16(33):2691-2700. PubMed ID: 32799562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A case report of a dramatic response to olaparib in a patient with metastatic pancreatic cancer harboring a germline BRCA2 mutation.
    Wang H; Mao C; Li N; Sun L; Zheng Y; Xu N
    Medicine (Baltimore); 2019 Oct; 98(40):e17443. PubMed ID: 31577767
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): a single-centre, parallel-group, non-comparative, randomised, phase 2 trial.
    Hu H; Kang L; Zhang J; Wu Z; Wang H; Huang M; Lan P; Wu X; Wang C; Cao W; Hu J; Huang Y; Huang L; Wang H; Shi L; Cai Y; Shen C; Ling J; Xie X; Cai Y; He X; Dou R; Zhou J; Ma T; Zhang X; Luo S; Deng W; Ling L; Liu H; Deng Y
    Lancet Gastroenterol Hepatol; 2022 Jan; 7(1):38-48. PubMed ID: 34688374
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systemic Therapy for Metastatic Pancreatic Cancer.
    Ettrich TJ; Seufferlein T
    Curr Treat Options Oncol; 2021 Oct; 22(11):106. PubMed ID: 34665339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of germline genetic mutations in patients with pancreatic cancer.
    Salo-Mullen EE; O'Reilly EM; Kelsen DP; Ashraf AM; Lowery MA; Yu KH; Reidy DL; Epstein AS; Lincoln A; Saldia A; Jacobs LM; Rau-Murthy R; Zhang L; Kurtz RC; Saltz L; Offit K; Robson ME; Stadler ZK
    Cancer; 2015 Dec; 121(24):4382-8. PubMed ID: 26440929
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.